Viral Infections Vaccines & Prevention Public Health

Hepatitis C elimination a 'political commitment challenge'

Share

Clinical Report: Hepatitis C Elimination: A Political Commitment Challenge

Overview

Speakers at IDWeek 2026 said that hepatitis C elimination requires expanded access to prevention, diagnosis and curative treatment, with political commitment and financing identified as major challenges. Global incidence and mortality reductions remain below 2030 targets. National programs and health-system initiatives illustrate approaches to expanding care, while hospital and emergency-department trials reported improvements in treatment initiation or diagnosis.

Background

World Health Organization estimates cited by John W. Ward, MD, indicated approximately 47 million people with hepatitis C worldwide, about 20% fewer than in 2015. Declines in incidence and deaths remained below the respective 2030 reduction goals of 90% and 65%.

Ward identified people who inject drugs and people who are incarcerated as populations requiring particular attention. He described limited access to prevention services and recommended stronger domestic financing, health-system prioritization and integration of testing and treatment into existing services. Other speakers addressed treatment delivery, populations facing care barriers and investigational tools.

Data Highlights

Measure or initiative

Reported result

Global hepatitis C burden

Approximately 47 million people worldwide; about 20% fewer than the 2015 estimate.

Global incidence and mortality change since 2015

Incidence declined about 8% versus a 90% reduction goal by 2030; deaths declined an estimated 12% versus a 65% reduction goal.

U.S. care cascade

Approximately 68% of patients with hepatitis C had been diagnosed; 43% of diagnosed patients had received treatment. The 2030 targets cited were 90% diagnosed and 80% of diagnosed patients treated.

Veterans Affairs system, 2021–2022

80% of veterans with hepatitis C who were in care had been treated; more than 90% of those treated achieved sustained virologic response.

OPPORTUNI-C trial, three Oslo hospitals

Treatment initiation within 6 months was 85.7% with assessment and treatment during hospitalization or soon after discharge, versus 46.1% with usual outpatient referral.

DETECT Hep C trial, three U.S. emergency departments

Nontargeted screening produced a 34% higher rate of hepatitis C diagnosis than targeted screening; substantial losses occurred between diagnosis and linkage to care.

England, 2015–2024

General-population prevalence declined 61% and mortality declined 18%.

Spain, 2015–2023

General-population prevalence declined 40%, mortality declined 53%, and prevalence among incarcerated people declined 92%.

Egypt

National prevalence declined from 10% to 0.4%.

Key Findings

  • Ward characterized elimination as increasingly a political commitment challenge rather than a scientific challenge. He called for domestic financing, health-system prioritization and integration of testing and treatment into existing services.

  • For people who inject drugs, Ward recommended combining counseling, sterile injection equipment, opioid substitution therapy, testing and treatment. He described limited availability of prevention services and identified confirmatory virologic testing costs as a major barrier.

  • National examples included England’s use of nonspecialist prescribing, peer navigation, no patient copays and no treatment restrictions. Spain emphasized harm reduction, correctional-setting testing and treatment, and simplified care pathways.

  • Norah Terrault, MD, MPH, described Veterans Affairs program components including multidisciplinary teams, telehealth, expanded prescribing capacity, integrated substance use care, patient tracking and treatment financing.

  • OPPORTUNI-C reported higher six-month treatment initiation with assessment and treatment during hospitalization or as soon as possible after discharge than with usual outpatient referral. DETECT Hep C reported higher diagnosis rates with nontargeted screening, but substantial losses before linkage to care.

  • Stacey B. Trooskin, MD, MPH, PhD, emphasized that active substance use is not a contraindication to treatment. In HERO, per-protocol sustained virologic response rates exceeded 90%; intention-to-treat rates were lower. A separate adherence analysis found response rates above 90% with medication adherence as low as 50%. She encouraged completion of all prescribed medication.

  • Trooskin advocated integrated care for populations facing barriers, including incarcerated people, pregnant people, children and men with HIV who have sex with men. Treatment during pregnancy is not universally recommended but may be considered individually after discussion of potential risks and benefits.

  • David Thomas, MD, MPH, reviewed a vaccine trial that generated immune responses but did not reduce progression to chronic infection. He also discussed preclinical injectable glecaprevir/pibrentasvir intended to deliver a complete curative course in one administration, with human testing planned for 2027.

Clinical Implications

The speakers described integrated care, nonspecialist prescribing, telehealth, hospital-based treatment and linkage support as approaches to addressing care gaps. Confirmatory testing costs and losses between diagnosis and treatment remained barriers.

Terrault advised treating acute hepatitis C upon confirmation without waiting for spontaneous clearance. She emphasized lifelong liver cancer surveillance after cure for patients who had cirrhosis before treatment and noted an association between metabolic dysfunction-associated steatotic liver disease and increased risk of liver complications after cure.

Trooskin recommended bringing testing and treatment into settings patients already use, supported by community partnerships and specialist consultation. She described routine opt-out screening and linkage upon release in correctional settings, infant testing after perinatal exposure, and approved antiviral treatment for children ages three and older with chronic infection.

Conclusion

National and health-system examples demonstrate progress toward expanding hepatitis C care, but global reductions remain below elimination targets. Speakers emphasized stronger political commitment, domestic financing and integrated access to prevention, diagnosis and treatment. Vaccine development and single-injection treatment remain investigational.

Related Resources & Content

  • Opportunistic Treatment of Hepatitis C Infection Among Hospitalized People Who Inject Drugs (OPPORTUNI-C): A Stepped Wedge Cluster Randomized Trial — Midgard H, Malme KB, Pihl CM, et al — Clinical Infectious Diseases — Published online November 22, 2023; 2024;78(3):582-590 — https://doi.org/10.1093/cid/ciad711. oup.silverchair-cdn.com

  • Hepatitis C Screening in Emergency Departments: The DETECT Hep C Randomized Clinical Trial — Haukoos J, Rothman RE, Galbraith JW, et al — JAMA — August 12, 2025;334(6):497-507 — https://doi.org/10.1001/jama.2025.10563. pubmed.ncbi.nlm.nih.gov

  • Patient-centred models of hepatitis C treatment for people who inject drugs: a multicentre, pragmatic randomised trial — Litwin AH, Lum PJ, Taylor LE, et al; HERO Study Group — The Lancet Gastroenterology & Hepatology — December 2022;7(12):1112-1127 — https://doi.org/10.1016/S2468-1253(22)00275-8. clinicaltrials.gov

  • Optimal hepatitis C treatment adherence patterns and sustained virologic response among people who inject drugs: The HERO study — Heo M, Norton BL, Pericot-Valverde I, et al; HERO Study Group — Journal of Hepatology — Published online January 17, 2024; May 2024;80(5):702-713 — https://doi.org/10.1016/j.jhep.2023.12.020. pubmed.ncbi.nlm.nih.gov

  • The role of prison-based interventions for hepatitis C virus (HCV) micro-elimination among people who inject drugs in Montréal, Canada — Godin A, Kronfli N, Cox J, Alary M, Maheu-Giroux M — International Journal of Drug Policy — Published online April 8, 2020; February 2021;88:102738 — https://doi.org/10.1016/j.drugpo.2020.102738.